Gyomor- és nyelőcsőrák: vizsgálatok itt: Kína
721 trials · From ClinicalTrials.gov, checked 2026. november 14.. Ask the study team whether a trial fits you.
- 1/2. fázisTaking peopleSubstudy 06C: A Study of Investigational Agents With Pembrolizumab (MK-3475) and Chemotherapy in Participants With First-Line Locally Advanced Unresectable/Metastatic Gastroesophageal Adenocarcinoma (MK-3475-06C/KEYMAKER-U06)
- Where
- Beijing, Fuzhou, Hangzhou, Nanchang, Shanghai, Ürümqi, Xiamen, Zhengzhou
- Életkor
- 18 év and over
- People
- 160 worldwide
- Run by
- Merck Sharp & Dohme LLC
See details and how to joinNCT06469944 · EU 2023-509307-33-00 - 1/2. fázisTaking peopleSubstudy 06E: Umbrella Study of Combination Therapies in Esophageal Cancer (MK-3475-06E/KEYMAKER-U06)
- Where
- Beijing, Hefei, Jinan, Nanchang, Xiamen, Xuzhou, Zhengzhou
- Életkor
- 18 év and over
- People
- 298 worldwide
- Run by
- Merck Sharp & Dohme LLC
See details and how to joinNCT06780111 · EU 2024-514273-22-00 - No phaseTaking peopleShanghai Clinical Cohort - Esophageal Cancer
- Where
- Shanghai
- People
- 3500
- Run by
- Shanghai Chest Hospital
See details and how to joinNCT07312526 - 1. fázisTaking peopleA Phase I Dose Escalation Study of CG-7321 Monotherapy or Combination Therapy in Advanced Solid Tumors
- Where
- Chengdu, Dalian, Fuzhou, Shanghai
- Életkor
- 18 év and over
- People
- 66
- Run by
- Chengdu Cynogen Bio-pharmaceutical Tech. Co., Ltd.
See details and how to joinNCT07923214 - 2/3. fázisNot yet taking people in KínaRC118 Combined With RC148 as First-Line Treatment for Claudin 18.2-Positive, HER2-Negative Advanced G/GEJ Adenocarcinoma
- Where
- Beijing, Shanghai
- Életkor
- 18 év and over
- People
- 680
- Run by
- RemeGen Co., Ltd.
See details and how to joinNCT07935369 - 1/2. fázisTaking peopleDual-target CLDN18.2/HER2 CAR-NK Cells for Advanced Gastric/GEJ Cancer
- Where
- Shenzhen
- Életkor
- 18 év to 75 év
- People
- 36
- Run by
- Beijing Biotech
See details and how to joinNCT07551362 - 1/2. fázisTaking peopleDual-Target CLDN18.2/HER2 CAR-NK Cells for Advanced Esophageal Adenocarcinoma
- Where
- Shenzhen
- Életkor
- 18 év to 75 év
- People
- 36
- Run by
- Beijing Biotech
See details and how to joinNCT07622940 - No phaseTaking peopleMultimodal Liquid-Biopsy Omics Biomarkers of Treatment Response in Breast Cancer
- Where
- Shanwei
- Életkor
- 18 év to 80 év
- People
- 2000
- Run by
- Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
See details and how to joinNCT07880106 - 2. fázisTaking peopleTotal Neoadjuvant Immunotherapy Plus Chemotherapy for Locally Advanced Gastric or Gastroesophageal Junction Adenocarcinoma
- Where
- Beijing, Guangzhou
- Életkor
- 18 év and over
- People
- 42
- Run by
- Beijing Tsinghua Chang Gung Hospital
See details and how to joinNCT07933471 - 2. fázisTaking peopleNeoadjuvant of Sintilimab Combined Weekly Metronomic Chemotherapy (POLF) for Resectable Locally Advanced Gastric Cancer
- Where
- Shanghai
- Életkor
- 18 év and over
- People
- 50
- Run by
- Huashan Hospital
See details and how to joinNCT06054906 - 1/2. fázisTaking peopleA Clinical Trial of Ifinatamab Deruxtecan in People With Advanced Esophageal Cancer (MK-3475-06F)
- Where
- Beijing, Hangzhou, Hefei, Jinan, Xiamen, Xuzhou, Zhengzhou
- Életkor
- 18 év and over
- People
- 60 worldwide
- Run by
- Merck Sharp & Dohme LLC
See details and how to joinNCT07405151 · EU 2026-525213-31-00 - 3. fázisTaking peopleA Study of ASP2138 Together With Chemotherapy and Pembrolizumab in Adults With Gastric Cancer
- Where
- Guangzhou
- Életkor
- 18 év and over
- People
- 570 worldwide
- Run by
- Astellas Pharma Global Development, Inc.
See details and how to joinNCT07673887 · EU 2025-524557-14-00 - 2. fázisTaking peoplePerioperative Chemotherapy With Low-Dose Radiotherapy and Tislelizumab for Locally Advanced Gastric or Gastroesophageal Junction Adenocarcinoma
- Where
- Nanjing
- Életkor
- 20 év to 80 év
- People
- 114
- Run by
- Jiangsu Cancer Institute & Hospital
See details and how to joinNCT07408609 - 1. fázisNot yet taking people in KínaGK01 Cell Therapy in Gastric Cancer With Peritoneal Metastasis
- Where
- Shanghai
- Életkor
- 18 év and over
- People
- 10
- Run by
- Ruijin Hospital
See details and how to joinNCT07923396 - 1/2. fázisTaking peopleBeamion BCGC-1: A Study to Find a Suitable Dose of Zongertinib Used Alone and in Combination With Other Treatments to Test Whether it Helps People With Different Types of HER2+ Cancer That Has Spread
- Where
- Changchun, Hangzhou, Harbin, Nanjing, Shanghai, Tianjin, Zhengzhou
- Életkor
- 18 év and over
- People
- 910 worldwide
- Run by
- Boehringer Ingelheim
See details and how to joinNCT06324357 - 3. fázisTaking peopleA Study of Zolbetuximab Together With Pembrolizumab and Chemotherapy in Adults With Gastric Cancer
- Where
- Baoding, Beijing, Chengdu, Fuzhou, Guangzhou, Hangzhou, Harbin, Hefei, Shanghai, Tianjin, Wuhan, Xining, Zhenngzhou
- Életkor
- 18 év and over
- People
- 500 worldwide
- Run by
- Astellas Pharma Global Development, Inc.
See details and how to joinNCT06901531 · EU 2024-519773-19-00 - 1. fázisTaking peopleA Study to Learn About the Study Medicine Called PF-08046876 in People With Advanced Solid Tumors
- Where
- Changsha
- Életkor
- 18 év and over
- People
- 540 worldwide
- Run by
- Pfizer
See details and how to joinNCT07090499 · EU 2025-521729-33-00 - 2/3. fázisTaking peopleA Study to Evaluate the Safety and Efficacy of Pumitamig in Combination With Chemotherapy Versus Nivolumab in Combination With Chemotherapy in Participants With Previously Untreated Advanced or Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma (ROSETTA Gastric-204)
- Where
- Beijing, Changsha, Chengdu, Fuzhou, Guangzhou, Hangzhou, Harbin, Jinan, Nanchang, Nanjing, Nanning, Shanghai, Shenyang, Taiyuan, Tianjin, Weihui, Wuhan, Yangzhou, Zhengzhou
- Életkor
- 18 év and over
- People
- 690 worldwide
- Run by
- Bristol-Myers Squibb
See details and how to joinNCT07221149 · EU 2025-523263-37-00 - 2. fázisTaking peopleCandonilimab Combined With Fruquintinib and Paclitaxel Albumin-Bound as Second-Line Treatment for Advanced Gastric or Gastro-esophageal Junction Adenocarcinoma
- Where
- Wuhan
- Életkor
- 18 év to 75 év
- People
- 59
- Run by
- Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
See details and how to joinNCT07920224 - 1. fázisTaking peopleA Study of LY4052031 in Participants With Advanced or Metastatic Urothelial Cancer or Other Solid Tumors
- Where
- Beijing, Guangzhou, Shanghai
- Életkor
- 18 év and over
- People
- 460 worldwide
- Run by
- Eli Lilly and Company
See details and how to joinNCT06465069 · EU 2024-512927-36-00 - 2. fázisTaking peopleA Study to Learn More About How Well Treatment With Sevabertinib (BAY 2927088) Tablets Works and How Safe it is in Participants Who Have a Solid Tumor With Mutations of the Human Epidermal Growth Factor Receptor 2 (HER2)
- Where
- Beijing, Changsha, Hangzhou, Shanghai
- Életkor
- 18 év and over
- People
- 111 worldwide
- Run by
- Bayer
See details and how to joinNCT06760819 · EU 2024-517419-62-00 - 1. fázisTaking peopleA Study of LY4257496 in Participants With Cancer (OMNIRAY)
- Where
- Beijing, Tianjin
- Életkor
- 18 év and over
- People
- 421 worldwide
- Run by
- Eli Lilly and Company
See details and how to joinNCT07114601 · EU 2025-522367-15-00 - 1. fázisTaking peopleA Study of LY4337713 in Participants With FAP-Positive Solid Tumors
- Where
- Shanghai
- Életkor
- 18 év and over
- People
- 340 worldwide
- Run by
- Eli Lilly and Company
See details and how to joinNCT07213791 · EU 2025-521887-37-00 - No phaseTaking peopleRemimazolam for Reducing Postoperative Delirium in Elderly Patients Undergoing Laparoscopic Gastrectomy
- Where
- Nanjing
- Életkor
- 65 év to 100 év
- People
- 170
- Run by
- The First Affiliated Hospital with Nanjing Medical University
See details and how to joinNCT07351474 - 1. fázisNot yet taking people in KínaSND002 Cell Injection in Participants With Advanced Malignant Solid Tumors
- Where
- Guiyang, Hangzhou
- Életkor
- 18 év to 80 év
- People
- 78
- Run by
- Guizhou Sinorda Pharmaceutical Co., Ltd.
See details and how to joinNCT07903857